Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant Staphylococcus aureus

被引：34

作者：

Tattevin, P. ^{[1
]}

Basuino, L. ^{[1
]}

Bauer, D. ^{[1
]}

Diep, B. A. ^{[1
]}

Chambers, H. F. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Div Infect Dis, San Francisco Gen Hosp, San Francisco, CA 94110 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 02期

关键词：

IN-VIVO EFFICACY; SKIN-STRUCTURE INFECTIONS; SPECTRUM CEPHALOSPORIN; COMPLICATED SKIN; DOUBLE-BLIND; BETA-LACTAM; MODEL; BACTEREMIA; COMBINATION; THERAPY;

D O I：

10.1128/AAC.00886-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Beta lactam agents are the most active drugs for the treatment of streptococci and methicillin-susceptible Staphylococcus aureus endocarditis. However, methicillin-resistant S. aureus (MRSA) is resistant to all beta lactam agents licensed to date, and alternative treatments are limited. Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the penicillin binding protein that mediates the methicillin resistance of staphylococci and is active against MRSA. Ceftobiprole was compared to vancomycin, daptomycin, and linezolid in a rabbit model of MRSA aortic valve endocarditis caused by the homogeneously methicillin-resistant laboratory strain COL. Residual organisms in vegetations were significantly fewer in ceftobiprole-treated rabbits than in any other treatment group (P < 0.05 for each comparison). In addition, the numbers of organisms in spleens and in kidneys were significantly lower in ceftobiprole-treated rabbits than in linezolid- and vancomycin-treated animals (P < 0.05 for each comparison). Anti-MRSA beta lactam agents such as ceftobiprole may represent a significant therapeutic advance over currently available agents for the treatment of MRSA endocarditis.

引用

页码：610 / 613

页数：4

共 37 条

[1]

[Anonymous], 2006, Drugs R D, V7, P305

[2]

Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564

[3] Epidemiology of methicillin-resistant Staphylococcus aureus [J].

Boucher, Helen W. ;

Corey, G. Ralph .

CLINICAL INFECTIOUS DISEASES, 2008, 46 :S344-S349

[4] Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus [J].

Boucher, Helen W. ;

Sakoulas, George .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :601-608

[5] Anti-MRSA β-lactams in development, with a focus on ceftobiprole:: the first anti-MRSA β-lactam to demonstrate clinical efficacy [J].

Bush, Karen ;

Heep, Markus ;

Macielag, Mark J. ;

Noel, Gary J. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (04) :419-429

[6] Daptomycin dose-effect relationship against resistant gram-positive organisms [J].

Cha, R ;

Grucz, RG ;

Rybak, MJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1598-1603

[7] Combating the growing problem of methicillin-resistant Staphylococcus aureus:: do the newer antibiotics represent a better alternative to vancomycin? [J].

Chambers, Henry F. ;

Hegde, Sharath S. .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (03) :333-335

[8] Ceftobiprole: in-vivo profile of a bactericidal cephalosporin [J].

Chambers, HF .

CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :17-22

[9] The changing epidemiology of Staphylococcus aureus? [J].

Chambers, HF .

EMERGING INFECTIOUS DISEASES, 2001, 7 (02) :178-182

[10] Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus [J].

Chambers, HF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :884-888

← 1 2 3 4 →